Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [654]
News [1409]
Articles [231]
Editorials [9]
Conferences [81]
elearning [12]
Targeted liver cancer treatment kills cancer cells and cuts chemo side effects
Targeted liver cancer treatment kills cancer cells and cuts chemo side effects
Sarcopenia-related traits, body mass index and ovarian cancer risk: Investigation of causal relationships through multivariable mendelian randomisation analyses
Sarcopenia-related traits, body mass index and ovarian cancer risk: Investigation of causal relationships through...
AACR 2024: Artificial intelligence analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer
AACR 2024: Artificial intelligence analysis of DNA fragmentomes and protein biomarkers noninvasively detects...
AACR 2024: Novel ADC and immunotherapy combo shows promise in endometrial cancer subtype
AACR 2024: Novel ADC and immunotherapy combo shows promise in endometrial cancer subtype
Novel theranostic tool allows for noninvasive identification and treatment of ovarian cancer
Novel theranostic tool allows for noninvasive identification and treatment of ovarian cancer
FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian...
Reducing the side effects of breast and ovarian cancer treatment
Reducing the side effects of breast and ovarian cancer treatment
Clinical trial shows rucaparib extends progression-free survival for uterine cancer patients
Clinical trial shows rucaparib extends progression-free survival for uterine cancer patients
Olaparib and durvalumab demonstrated strong clinical benefit in mismatch repair proficient advanced or recurrent endometrial cancer
Olaparib and durvalumab demonstrated strong clinical benefit in mismatch repair proficient advanced or recurrent...
Targeting LTA4H improves the tumor immune microenvironment and is expected to be a new treatment strategy for ovarian cancer
Targeting LTA4H improves the tumor immune microenvironment and is expected to be a new treatment strategy for...

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation